Research programme: CNS therapeutics - Ms ScienceAlternative Names: MC 116
Latest Information Update: 21 Jan 2016
At a glance
- Originator Ms Science
- Mechanism of Action Sigma-1 receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical CNS disorders
Most Recent Events
- 21 Jan 2016 Preclinical trials in CNS disorders in Japan (unspecified route) before January 2016